Connexin gene transfer preserves conduction velocity and prevents atrial fibrillation

Tomonori Igarashi, J. Emanuel Finet, Ayano Takeuchi, Yoshihisa Fujino, Maria Strom, Ian D. Greener, David S. Rosenbaum, J. Kevin Donahue

Research output: Contribution to journalArticle

111 Citations (Scopus)

Abstract

Background - Several lines of evidence have suggested that maintenance of atrial fibrillation (AF) depends on reentrant mechanisms. Maintenance of reentry necessitates a sufficiently short refractory period and/or delayed conduction, and AF has been associated with both alterations. Fibrosis, cellular dysfunction, and gap junction protein alterations occur in AF and cause conduction delay. We performed this study to test the hypothesis that gap junction protein overexpression would improve conduction and prevent AF. Methods and Results - Thirty Yorkshire swine were randomized into 2 groups (sinus rhythm and AF), and each group into 3 subgroups: sham-operated control, gene therapy with adenovirus expressing connexin (Cx) 40, and gene therapy with adenovirus expressing Cx43 (n=5 per subgroup). All animals had epicardial gene painting; the AF group had burst atrial pacing. All animals underwent terminal study 7 days after gene transfer. Sinus rhythm animals had strong transgene expression but no atrial conduction changes. In AF animals, controls had reduced and lateralized Cx43 expression, and Cx43 gene transfer restored expression and cellular location to sinus rhythm control levels. In the AF group, both Cx40 and Cx43 gene transfer improved conduction and reduced AF relative to controls. Conclusions - Connexin gene therapy preserved atrial conduction and prevented AF.

Original languageEnglish
Pages (from-to)216-225
Number of pages10
JournalCirculation
Volume125
Issue number2
DOIs
Publication statusPublished - 2012 Jan 17
Externally publishedYes

Fingerprint

Connexins
Atrial Fibrillation
Connexin 43
Genes
Genetic Therapy
Adenoviridae
Maintenance
Paintings
Transgenes
Fibrosis
Swine
Gene Expression

Keywords

  • atrial fibrillation
  • connexin
  • gap junction protein
  • gene therapy

ASJC Scopus subject areas

  • Physiology (medical)
  • Cardiology and Cardiovascular Medicine

Cite this

Igarashi, T., Finet, J. E., Takeuchi, A., Fujino, Y., Strom, M., Greener, I. D., ... Donahue, J. K. (2012). Connexin gene transfer preserves conduction velocity and prevents atrial fibrillation. Circulation, 125(2), 216-225. https://doi.org/10.1161/CIRCULATIONAHA.111.053272

Connexin gene transfer preserves conduction velocity and prevents atrial fibrillation. / Igarashi, Tomonori; Finet, J. Emanuel; Takeuchi, Ayano; Fujino, Yoshihisa; Strom, Maria; Greener, Ian D.; Rosenbaum, David S.; Donahue, J. Kevin.

In: Circulation, Vol. 125, No. 2, 17.01.2012, p. 216-225.

Research output: Contribution to journalArticle

Igarashi, T, Finet, JE, Takeuchi, A, Fujino, Y, Strom, M, Greener, ID, Rosenbaum, DS & Donahue, JK 2012, 'Connexin gene transfer preserves conduction velocity and prevents atrial fibrillation', Circulation, vol. 125, no. 2, pp. 216-225. https://doi.org/10.1161/CIRCULATIONAHA.111.053272
Igarashi, Tomonori ; Finet, J. Emanuel ; Takeuchi, Ayano ; Fujino, Yoshihisa ; Strom, Maria ; Greener, Ian D. ; Rosenbaum, David S. ; Donahue, J. Kevin. / Connexin gene transfer preserves conduction velocity and prevents atrial fibrillation. In: Circulation. 2012 ; Vol. 125, No. 2. pp. 216-225.
@article{f3613f4d23274b8a95eb5234b0e1f7b7,
title = "Connexin gene transfer preserves conduction velocity and prevents atrial fibrillation",
abstract = "Background - Several lines of evidence have suggested that maintenance of atrial fibrillation (AF) depends on reentrant mechanisms. Maintenance of reentry necessitates a sufficiently short refractory period and/or delayed conduction, and AF has been associated with both alterations. Fibrosis, cellular dysfunction, and gap junction protein alterations occur in AF and cause conduction delay. We performed this study to test the hypothesis that gap junction protein overexpression would improve conduction and prevent AF. Methods and Results - Thirty Yorkshire swine were randomized into 2 groups (sinus rhythm and AF), and each group into 3 subgroups: sham-operated control, gene therapy with adenovirus expressing connexin (Cx) 40, and gene therapy with adenovirus expressing Cx43 (n=5 per subgroup). All animals had epicardial gene painting; the AF group had burst atrial pacing. All animals underwent terminal study 7 days after gene transfer. Sinus rhythm animals had strong transgene expression but no atrial conduction changes. In AF animals, controls had reduced and lateralized Cx43 expression, and Cx43 gene transfer restored expression and cellular location to sinus rhythm control levels. In the AF group, both Cx40 and Cx43 gene transfer improved conduction and reduced AF relative to controls. Conclusions - Connexin gene therapy preserved atrial conduction and prevented AF.",
keywords = "atrial fibrillation, connexin, gap junction protein, gene therapy",
author = "Tomonori Igarashi and Finet, {J. Emanuel} and Ayano Takeuchi and Yoshihisa Fujino and Maria Strom and Greener, {Ian D.} and Rosenbaum, {David S.} and Donahue, {J. Kevin}",
year = "2012",
month = "1",
day = "17",
doi = "10.1161/CIRCULATIONAHA.111.053272",
language = "English",
volume = "125",
pages = "216--225",
journal = "Circulation",
issn = "0009-7322",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Connexin gene transfer preserves conduction velocity and prevents atrial fibrillation

AU - Igarashi, Tomonori

AU - Finet, J. Emanuel

AU - Takeuchi, Ayano

AU - Fujino, Yoshihisa

AU - Strom, Maria

AU - Greener, Ian D.

AU - Rosenbaum, David S.

AU - Donahue, J. Kevin

PY - 2012/1/17

Y1 - 2012/1/17

N2 - Background - Several lines of evidence have suggested that maintenance of atrial fibrillation (AF) depends on reentrant mechanisms. Maintenance of reentry necessitates a sufficiently short refractory period and/or delayed conduction, and AF has been associated with both alterations. Fibrosis, cellular dysfunction, and gap junction protein alterations occur in AF and cause conduction delay. We performed this study to test the hypothesis that gap junction protein overexpression would improve conduction and prevent AF. Methods and Results - Thirty Yorkshire swine were randomized into 2 groups (sinus rhythm and AF), and each group into 3 subgroups: sham-operated control, gene therapy with adenovirus expressing connexin (Cx) 40, and gene therapy with adenovirus expressing Cx43 (n=5 per subgroup). All animals had epicardial gene painting; the AF group had burst atrial pacing. All animals underwent terminal study 7 days after gene transfer. Sinus rhythm animals had strong transgene expression but no atrial conduction changes. In AF animals, controls had reduced and lateralized Cx43 expression, and Cx43 gene transfer restored expression and cellular location to sinus rhythm control levels. In the AF group, both Cx40 and Cx43 gene transfer improved conduction and reduced AF relative to controls. Conclusions - Connexin gene therapy preserved atrial conduction and prevented AF.

AB - Background - Several lines of evidence have suggested that maintenance of atrial fibrillation (AF) depends on reentrant mechanisms. Maintenance of reentry necessitates a sufficiently short refractory period and/or delayed conduction, and AF has been associated with both alterations. Fibrosis, cellular dysfunction, and gap junction protein alterations occur in AF and cause conduction delay. We performed this study to test the hypothesis that gap junction protein overexpression would improve conduction and prevent AF. Methods and Results - Thirty Yorkshire swine were randomized into 2 groups (sinus rhythm and AF), and each group into 3 subgroups: sham-operated control, gene therapy with adenovirus expressing connexin (Cx) 40, and gene therapy with adenovirus expressing Cx43 (n=5 per subgroup). All animals had epicardial gene painting; the AF group had burst atrial pacing. All animals underwent terminal study 7 days after gene transfer. Sinus rhythm animals had strong transgene expression but no atrial conduction changes. In AF animals, controls had reduced and lateralized Cx43 expression, and Cx43 gene transfer restored expression and cellular location to sinus rhythm control levels. In the AF group, both Cx40 and Cx43 gene transfer improved conduction and reduced AF relative to controls. Conclusions - Connexin gene therapy preserved atrial conduction and prevented AF.

KW - atrial fibrillation

KW - connexin

KW - gap junction protein

KW - gene therapy

UR - http://www.scopus.com/inward/record.url?scp=84856087307&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856087307&partnerID=8YFLogxK

U2 - 10.1161/CIRCULATIONAHA.111.053272

DO - 10.1161/CIRCULATIONAHA.111.053272

M3 - Article

C2 - 22158756

AN - SCOPUS:84856087307

VL - 125

SP - 216

EP - 225

JO - Circulation

JF - Circulation

SN - 0009-7322

IS - 2

ER -